AtriCure, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AtriCure, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $52.89M | Mar 1, 2019 |
| FY2018 | Sep 30, 2018 | $49.94M | Mar 1, 2019 |
| FY2018 | Jun 30, 2018 | $51.80M | Mar 1, 2019 |
| FY2018 | Mar 31, 2018 | $46.99M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $46.06M | Mar 1, 2019 |
| FY2018 | Sep 30, 2017 | $42.15M | Mar 1, 2019 |
| FY2018 | Jun 30, 2017 | $45.23M | Mar 1, 2019 |
| FY2018 | Mar 31, 2017 | $41.27M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $41.16M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $38.34M | Feb 28, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $534.53M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $465.31M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $399.25M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $330.38M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $274.33M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $57.73M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $54.76M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $40.82M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $53.23M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $61.32M | Feb 26, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $347.52M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $300.37M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $245.94M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $205.86M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $42.44M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $40.33M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $27.65M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $38.88M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $44.77M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.45M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($44.70M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($30.44M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($46.47M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $50.20M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | ($18.56M) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | ($4.95M) | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | ($8.24M) | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | ($16.41M) | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($16.10M) | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.45M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($40.01M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($26.68M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($42.67M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $55.21M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | ($17.50M) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | ($3.99M) | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | ($7.29M) | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | ($15.45M) | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($15.33M) | Feb 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.21M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $96.18M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $73.92M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $57.34M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $48.51M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $43.07M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $41.23M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $34.72M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $34.14M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $35.82M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $311.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $291.36M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $253.14M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $231.27M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $204.65M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $150.83M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $167.14M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $129.52M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $117.00M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $106.42M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.33M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $12.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $4.48M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($22.14M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($13.78M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | ($19.87M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($15.81M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($4.17M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($8.94M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($15.12M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.05M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $11.46M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $12.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $16.88M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $9.75M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $5.26M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $12.18M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $6.21M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $6.38M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $7.69M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $654.18M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $609.33M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $613.93M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $585.45M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $615.31M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $714.54M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $557.88M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $356.76M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $267.70M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $276.42M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.24M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $148.36M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $147.76M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $128.69M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $131.56M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $302.15M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $310.54M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $107.38M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $106.54M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $107.98M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.94M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $460.97M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $466.17M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $456.75M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $483.76M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $412.39M | Feb 16, 2024 |
| FY2022 | Dec 31, 2019 | $247.34M | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $249.38M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $161.17M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $168.44M | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $234.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $234.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $234.78M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $234.78M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $234.78M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $234.78M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $234.78M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $105.26M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $105.26M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $105.26M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($413.20M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($401.76M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($357.06M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($326.62M) | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | ($280.15M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($330.35M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($282.20M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($247.00M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | ($225.87M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($198.97M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.43M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $122.72M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $84.31M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $58.10M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $43.65M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $41.94M | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $28.48M | Feb 17, 2022 |
| FY2021 | Dec 31, 2018 | $32.23M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $21.81M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $24.21M | Feb 24, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 5, 2024 | $61.00M | Feb 19, 2026 |
| FY2022 | Dec 31, 2022 | $60.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2021 | $60.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2020 | $60.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2019 | $60.00M | Feb 24, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.79M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 48.87M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 47.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 46.56M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 46.02M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 45.35M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 39.66M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 38.60M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 34.59M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 33.34M | Feb 28, 2018 |